Ascendis Pharma A/S
ASND
171 hedge funds and large institutions have $7.24B invested in Ascendis Pharma A/S in 2021 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 73 increasing their positions, 50 reducing their positions, and 26 closing their positions.
46% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 50
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
6% more capital invested
Capital invested by funds: $6.83B → $7.24B (+$411M)
3.95% more ownership
Funds ownership: 98.47% → 102.42% (+3.9%)
3% less funds holding
Funds holding: 177 → 171 (-6)
15% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 26
78% less call options, than puts
Call options by funds: $15.9M | Put options by funds: $70.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$253M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$56.6M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$52.5M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$51M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$42.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$83.3M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$66.8M |
| 3 |
Neuberger Berman Group
New York
|
-$24.6M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$22.9M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$18.4M |
ASND Hedge Fund Activity: Q2 2021 in Review
171 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2021, worth a combined $7.24B — up 6% from $6.83B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ASND and 22 opened new positions — a net loss of 4 holders — while 50 trimmed existing stakes and 73 added.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $253M. The largest seller was Farallon Capital Management, cutting an estimated $83.3M.
- 171 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2021, down from 177 in Q1 2021.
- Funds reported $7.24B of Ascendis Pharma A/S stock for Q2 2021, up 6% quarter-over-quarter.
- 22 funds opened new Ascendis Pharma A/S positions in Q2 2021 and 26 closed out, a net change of -4 holders.
- The largest Ascendis Pharma A/S buyer in Q2 2021 was Avoro Capital Advisors, an estimated $253M added.
- The largest Ascendis Pharma A/S seller in Q2 2021 was Farallon Capital Management, an estimated $83.3M sold.
Based on aggregated 13F filings for Q2 2021.